1.Differential Blast Counts Obtained by Automated Blood Cell Analyzers.
Seungwon JUNG ; Hyojin CHAE ; Jihyang LIM ; Eun Jee OH ; Yonggoo KIM ; Yeon Joon PARK ; Kyungja HAN
The Korean Journal of Laboratory Medicine 2010;30(6):540-546
BACKGROUND: Automated blood cell analyzers often read leukemic blasts as normal cells. In this study, we evaluated the 5-part differential patterns of blasts using automated analyzers to determine if they can differentiate among blast types. METHODS: Blood samples containing 10% or more blasts were collected from patients with acute leukemia (N=175). The 5-part differential count was conducted using DxH 800 (Beckman Coulter, USA) and XE-2100 analyzers (Sysmex Co., Japan), and the results were compared with manual differential counts, which was used as a reference method. RESULTS: The DxH 800 reported the 5-part white blood cell differential count in 98.9% of the cases. The XE-2100 provided an invalid automated differential count in 72% of the cases. Both analyzers counted most lymphoblasts as lymphocytes and most myeloblasts as monocytes. In 11 cases, the DxH 800 reported a 5-part differential count without a blast flag. CONCLUSIONS: Some automated analyzers are able to recognize and count blasts according to their characteristic cell types. Therefore, complete blood counts obtained automatically can provide valuable data for making provisional decisions regarding the lineage of leukemia cells before further investigation.
Acute Disease
;
Automation
;
Blood Cell Count/*instrumentation/methods
;
Humans
;
Leukemia/blood/*diagnosis
;
Leukemia, Monocytic, Acute/blood/diagnosis
;
Leukemia, Myeloid, Acute/blood/diagnosis
;
Leukemia, Promyelocytic, Acute/blood/diagnosis
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood/diagnosis
2.Hypersensitivity Reaction as a Harbinger of Acute Myeloid Leukemia: A Case Report and Review of the Literature.
Jeffrey M COHEN ; Carol E CHENG ; Aieska DESOUZA ; Tina R NANDI ; Elizabeth A BUZNEY ; Allison LARSON ; Winston Y LEE ; Arash MOSTAGHIMI
Annals of Dermatology 2015;27(2):190-193
Cutaneous paraneoplastic syndromes comprise a broad spectrum of cutaneous reactions to an underlying malignancy. These dermatoses are not the result of metastatic spread to the skin, but rather a reaction to the presence of malignancy. Cutaneous paraneoplastic syndromes often precede the identification of a malignancy. We describe the case of a 79-year-old man with a six-month history of recalcitrant treatment- resistant dermatitis. A complete blood count test performed at the time of initial presentation was normal. The patient ultimately presented with erythroderma and was diagnosed with acute myeloid leukemia (AML). The evolution of the dermatitis to erythroderma coincided with the clinical presentation of AML, and was therefore considered to be a paraneoplastic syndrome. The patient decided against therapy and died seven weeks after diagnosis. Physicians should consider a cutaneous paraneoplastic syndrome when faced with dynamic recalcitrant dermatoses that are difficult to treat and decide on laboratory testing accordingly. Patients should be evaluated regularly for two to three years after initial diagnosis with a physical exam and review of systems to monitor for signs and symptoms of malignancy.
Aged
;
Blood Cell Count
;
Dermatitis
;
Dermatitis, Exfoliative
;
Diagnosis
;
Humans
;
Hypersensitivity*
;
Leukemia
;
Leukemia, Myeloid, Acute*
;
Paraneoplastic Syndromes
;
Skin
;
Skin Diseases
3.Delta Neutrophil Index as an Early Marker for Distinguishing Myeloid from Childhood Acute Leukemia.
Joon Pyo HONG ; Sohyun KIM ; Byuh Ree KIM ; Seo Hee YOON ; Seung Min HAHN ; Moon Kyu KIM
Clinical Pediatric Hematology-Oncology 2018;25(2):128-135
BACKGROUND: The accurate and early diagnosis of acute myeloid leukemia (AML) is important to choose proper treatment option depending on the risk stratification. The delta neutrophil index (DNI) is a relatively new blood marker that indicates the proportion of immature granulocytes in peripheral blood circulation. This study aimed to evaluate the diagnostic value of the DNI for detecting AML in the early phase of acute leukemia. METHODS: We retrospectively analyzed laboratory tests and bone marrow study results of 163 pediatric patients with acute leukemia admitted to the emergency department, who were diagnosed with acute leukemia. An automatic analyzer (ADVIA 2120 Hematology System; Siemens Healthcare Diagnostics, Forchheim, Germany) was used to measure the DNI in the peripheral blood of each patient. RESULTS: The mean DNI was significantly different between the AML (N=39) and non-AML (N=124) groups (P < 0.05), and the DNI was the only significant marker for predicting AML in patients with acute leukemia (odds ratio, 1.328; P < 0.05). The DNI more than 4.4% has the highest predictability for distinguishing the patients with AML from the patients with acute leukemia. The mean DNI of the acute promyelocytic leukemia (APL, N=8) group was statistically higher than that of the non-APL group (N=31, P=0.019), but the DNI was not significant in the univariate logistic regression analysis. CONCLUSION: The DNI might be a promising peripheral blood marker for predicting AML in the early work-up of patients with acute leukemia.
Blood Circulation
;
Bone Marrow
;
Child
;
Delivery of Health Care
;
Early Diagnosis
;
Emergency Service, Hospital
;
Granulocytes
;
Hematology
;
Humans
;
Leukemia*
;
Leukemia, Myeloid, Acute
;
Leukemia, Promyelocytic, Acute
;
Logistic Models
;
Neutrophils*
;
Retrospective Studies
4.Detection of cytokine expression patterns in the peripheral blood of patients with acute leukemia by antibody microarray analysis.
Qing LI ; Mei LI ; Yao-hui WU ; Xiao-jian ZHU ; Chen ZENG ; Ping ZOU ; Zhi-chao CHEN
Journal of Huazhong University of Science and Technology (Medical Sciences) 2014;34(2):176-180
The cytokines of acute leukemia (AL) patients have certain expression patterns, forming a complex network involved in diagnosis, progression, and prognosis. We collected the serum of different AL patients before and after complete remission (CR) for detection of cytokines by using an antibody chip. The expression patterns of cytokines were determined by using bioinformatics computational analysis. The results showed that there were significant differences in the cytokine expression patterns between AL patients and normal controls, as well as between acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In confirmatory test, ELISA revealed the expression of uPAR in AL. Moreover, the bioinformatic analysis showed that the differentially expressed cytokines among the AL groups were involved in different biological behaviors and were closely related with the development of the disease. It was concluded that the cytokine expression pattern of AL patients is significantly different from that of healthy volunteers. Also, differences of cytokine expression patterns exist between AML and ALL, and between before and after CR in the same subtype of AL, which holds important clinical significance for revealing disease progression.
Cytokines
;
biosynthesis
;
blood
;
Diagnosis, Differential
;
Gene Expression Regulation, Leukemic
;
Humans
;
Leukemia, Myeloid, Acute
;
blood
;
Microarray Analysis
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
blood
;
Prognosis
;
RNA, Messenger
;
biosynthesis
;
blood
5.The Clinical Features and Prognosis of Leukemia in Down Syndrome.
Ye Na CHOI ; Jee Hyun CHUN ; Seung Hwan OH ; Chuhl Joo LYU ; Chang Hyun YANG ; Kir Young KIM
Korean Journal of Pediatric Hematology-Oncology 2002;9(2):186-192
PURPOSE: There are several reports that the risk of development of leukemias is much higher in Down syndrome (DS) children than in non DS children. But there are a few reports about the clinical features of leukemia in Down syndrome and the prognosis in Korea. The object of this study is to evaluate clinical features, treatment results and the prognosis of leukemia of Down syndrome patients. METHODS: We conducted retrospective reviews in 10 children with leukemia of Down syndrome who were admitted to the Department of Pediatrics in Yonsei University Hospital between March 1986 and December 2000. We analyzed the clinical features, laboratory findings and survival rates. RESULTS: A male to female ratio was 1:1.25. Median age at diagnosis was 2 years 8 months. Initial symptoms were hepatosplenomegaly, petechiae, fever and upper respiratory infection symptoms. The number of patients by the type was as followed:acute myeloid leukemia (AML) 7 (70%), acute lymphocytic leukemia 2 (20%), acute mixed lineage leukemia 1 (10%). There were 4 cases of M7 subtype in AML. The median peripheral blood cell counts were as followed; leukocyte was 41,000/muL, hemoglobin was 8.7 g/dL, the platelet was 103,000/muL. The five years event free survival rate after diagnosis was 87.5% (7/8). The one patient relapsed and another one patient died of cardiac anomaly. CONCLUSION: There seemed to be several differences of clinical features between DS leukemia and non DS leukemia, especially prognosis. Multi-centered well organized study should be done to confirm our observation.
Blood Cell Count
;
Blood Platelets
;
Child
;
Chromosomes, Human, Pair 21
;
Diagnosis
;
Disease-Free Survival
;
Down Syndrome*
;
Female
;
Fever
;
Humans
;
Korea
;
Leukemia*
;
Leukemia, Myeloid
;
Leukemia, Myeloid, Acute
;
Leukocytes
;
Male
;
Pediatrics
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
Prognosis*
;
Purpura
;
Retrospective Studies
;
Survival Rate
6.Cell Population Data NE-SFL and MO-WX From Sysmex XN-3000 Can Provide Additional Information for Exclusion of Acute Promyelocytic Leukemia From Other Acute Myeloid Leukemias: A Preliminary Study.
Sang Hyuk PARK ; Hyung Hoi KIM ; In Suk KIM ; Jongyoun YI ; Chulhun L CHANG ; Eun Yup LEE
Annals of Laboratory Medicine 2016;36(6):607-610
No abstract available.
Adult
;
Aged
;
Aged, 80 and over
;
Area Under Curve
;
Automation
;
Blood Cell Count/instrumentation/*methods
;
Female
;
Humans
;
Leukemia, Myeloid, Acute/*diagnosis
;
Leukemia, Promyelocytic, Acute/*diagnosis
;
Male
;
Middle Aged
;
Prospective Studies
;
ROC Curve
;
Young Adult
7.Abnormal expression of hematopoietic regulatory factors in newly diagnosed patients with acute myeloid leukemia.
Rong XIAO ; Tao CHEN ; Min ZHOU ; Jian-He YANG ; Nai-Ke JIANG ; Ri ZHANG
Journal of Experimental Hematology 2010;18(5):1124-1127
The aim of this study was to detect the expressions of transforming growth factor (TGFβ(1)), tumor necrosis factor alpha (TNFα) and leukemia inhibitory factor (LIF) in newly diagnosed patients with acute myeloid leukemia (AML) and investigate the association between serum levels of various cytokines and clinical outcomes. The levels of TGFβ1, TNFα and LIF in patient's plasma were detected by enzyme-linked immunosorbent assays (ELISA) and were compared with healthy controls; bone marrow cell morphology, immunology, cytogenetics examinations (MIC) were performed meanwhile. The results showed that levels of TGFβ1, TNFα and LIF were elevated in AML patients as compared with the controls (13.08±9.77 ng/ml, 10.67±15.11 pg/ml, 4.23±4.73 pg/ml vs 8.23±3.12 ng/ml, 5.86±3.05 pg/ml, 2.78±1.22 pg/ml) (p all<0.05). The three cytokines and MIC examination analysis indicated that level of LIF was abnormally elevated in M5 patients (7.14±6.62 pg/ml); TNFα was abnormally elevated in M4 and M3 patients especially M4; TGFβ1 level in M6 and M2 patients was higher than others. TGFβ1 plasma concentration in low-risk group the lowest (10.45±4.73 ng/ml), and that in middle risk group was the highest (16.13±13.76 ng/ml) (p<0.05); the levels of other two kinds of factors in the chromosome karyotype groups showed no significant difference. It is concluded that TGFβ1, TNFα and LIF expressions showed increased level in the untreated patients with de novo AML, the TGFβ1 level among which is associated with the prognosis of patients.
Adolescent
;
Adult
;
Aged
;
Case-Control Studies
;
Female
;
Hematopoietic System
;
metabolism
;
Humans
;
Karyotyping
;
Leukemia Inhibitory Factor
;
blood
;
Leukemia, Myeloid, Acute
;
blood
;
diagnosis
;
genetics
;
Male
;
Middle Aged
;
Neoplasm Staging
;
Prognosis
;
Transforming Growth Factor beta1
;
blood
;
Tumor Necrosis Factor-alpha
;
blood
;
Young Adult
8.Five cases of cytomegalovirus infection detected by in situ hybridization and antigenemia assay.
Jin Hong YOO ; Jong Young CHOI ; Yang Ree KIM ; Yeong Jin CHOI ; Sang In SHIM ; Hak Ki KIM ; Chul Woo YANG ; Yong Soo KIM ; Chi Wha HAHN ; Wan Shik SHIN ; Chong Won PARK ; Moon Won KANG ; Choon Choo KIM ; Byung Kee BANG ; Dong Jip KIM
Journal of Korean Medical Science 1994;9(6):507-512
We report five cases of cytomegalovirus infection in immunocompromised patients which were detected by either cytomegalovirus antigenemia assay or in situ hybridization. Four cases had leukemia and the other had chronic renal failure. All the three BMT recipients suffered from GvHD. Interestingly, there was an unique case of CMV disease without a history of BMT, which reminded us that CMV could attack immunocompromised patients who had not undergone transplantation, too. Four out of five cases died. We think that cytomegalovirus infection or disease should not be regarded as a minor problem in post-transplantation infection in Korea.
Adolescent
;
Adult
;
Antigens, Viral/*blood
;
*Bone Marrow Transplantation
;
Case Report
;
Cytomegalovirus/*immunology
;
Cytomegalovirus Infections/complications/*diagnosis
;
Fatal Outcome
;
Graft vs Host Disease/complications
;
Human
;
Immunocompromised Host
;
In Situ Hybridization
;
Kidney Failure, Chronic/complications
;
Kidney Transplantation
;
Leukemia/*complications/therapy
;
Leukemia, Lymphocytic, Acute, L2/complications/therapy
;
Leukemia, Myelocytic, Acute/complications/therapy
;
Leukemia, Myeloid, Chronic/complications/therapy
;
Male
;
Viremia/*diagnosis
9.Detection of residual leukemic cells after complete remission of patients with acute myeloid leukemia.
Yan-Li XU ; Xue-Zhong ZHANG ; Lei ZHANG ; Xiu-Qun ZHANG
Journal of Experimental Hematology 2004;12(6):858-860
The aim was to study minimal residual disease (MRD) in blood and bone marrow after complete remission of patients with acute myeloid leukemia (AML) and explore the role of MRD in detecting relapse of acute myeloid leukemia. The blood and bone marrow samples from 33 AML patients who had been in complete remission were determined for residual leukemic cells (RLC) with flow cytometry. The results showed that RLC in AML group of complete remission was higher than that of normal group both in blood by (4.7518 +/- 4.1537)% vs (0.4835 +/- 0.2005)% and bone marrow by (17.9082 +/- 20.4819)% vs (0.7285 +/- 0.2209)%, while the RLC in relapsed group was higher than that in non-relapsed group both in blood by (2.233 +/- 1.5923)% vs (10.2369 +/- 9.4714)% and bone marrow by (4.779 +/- 3.0336)% vs (38.0685 +/- 19.4295)%. In conclusion, early detection of leukemic residual cells with flow cytometry contributes to treatment of relapse in time.
Acute Disease
;
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Bone Marrow Cells
;
pathology
;
Female
;
Flow Cytometry
;
Humans
;
Leukemia, Myeloid
;
blood
;
pathology
;
therapy
;
Male
;
Middle Aged
;
Neoplasm, Residual
;
blood
;
diagnosis
;
Remission Induction
10.Preliminarily screening of serum characteristic markers in acute myeloid leukemia and clinical significance.
Ai-Li HE ; Ju BAI ; Chen HUANG ; Wang-Gang ZHANG ; Juan YANG ; Jian-Li WANG ; Xin MENG ; Wei TIAN
Journal of Experimental Hematology 2010;18(5):1132-1137
This study was purposed to preliminarily screen characteristic tumor markers of acute myeloid leukemia (AML) and to investigate the serum proteomics characteristics of patients with AML and their significance in pathogenesis. 14 patients with AML and 28 healthy controls were enrolled in this study. The serum protein components were captured by weak cation exchange nanometer magnetic beads, the protein mass-spectra of all samples were detected by Autoflex II matrix-assisted laser desorption/ionization time of flight mass spectrometer, and the detection data were analyzed by means of CliprotoolsTM2.2 software, then the differential protein molecules were screened and the diagnostic model was established. Sera of 7 AML patients and 14 healthy controls were selected to verify the established model by using blind test. The results indicated that about 69 protein peaks could be detected within the range of 0.7-10 kD in protein spectra of serum samples from AML patients and controls. Compared with healthy controls, there were 44 statistically differential expression peaks in AML group (p<0.0001). Among them, 10 protein peaks were upregulated protein peaks and 34 protein peaks were downregulated. Diagnostic model was established on the basis of Quick Classifier Algorithm (QC), and the three mass peaks had the strongest power for software to automatically distinguish AML group from control group. Mass charge ratios (m/z) were 3216.57, 4089.7, and 7762.87 respectively. Sensitivity was expected as 86.4% while 82.8% in this established model group. Category validation showed that this diagnostic model correctly identified all 6 cases out of AML and 12 cases out of 14 healthy controls. In cross validation, the model sensitivity and specificity both were 85.7%. It is concluded that the AML QC model is composed of three protein peaks, which can effectively distinguish AML patients from healthy controls. Owing to higher sensitivity and specificity, they may act as serum tumor markers of AML. Among the three proteins, the one with m/z 7762.87 is the platelet-derived protein chemokine (PF4) protein. This finding will probably provide significant experimental evidence for understanding pathogenesis, molecular type, prognosis and treatment effect of AML.
Adult
;
Aged
;
Biomarkers
;
Biomarkers, Tumor
;
blood
;
Case-Control Studies
;
Female
;
Humans
;
Leukemia, Myeloid, Acute
;
blood
;
diagnosis
;
Male
;
Middle Aged
;
Prognosis
;
Protein Array Analysis
;
methods
;
Proteomics
;
Sensitivity and Specificity
;
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
;
methods
;
Young Adult